Differences

This shows you the differences between two versions of the page.

--- stephanie_carlin [2022/05/01 20:44]
liam
+++ stephanie_carlin [2022/05/01 20:55] (current)
liam [Funding]
@@ Line 17: / Line 17: @@
 ==== Hamilton Health Sciences ====
-Carlin is a critical care pharmacist at [[Hamilton Health Sciences]].((//Stephanie Carlin · Pharmacist · Hamilton Health Sciences.// OpenGovCA. Retrieved May 1, 2022, from https://web.archive.org/web/20220501183726/https://opengovca.com/ontario-employee/stephanie-carlin))
+Carlin was a critical care pharmacist, and now a thrombosis pharmacist, at [[Hamilton Health Sciences]].((//Stephanie Carlin · Pharmacist · Hamilton Health Sciences.// OpenGovCA. Retrieved May 1, 2022, from https://web.archive.org/web/20220501183726/https://opengovca.com/ontario-employee/stephanie-carlin))
 ==== Ontario COVID-19 Science Advisory Table ====
@@ Line 26: / Line 26: @@
 Her research interests include optimization of antithrombotic use in clinical practice.
+==== Funding ====
+Carlin received funding from [[pharmaceutical_companies:Sanofi]] for her advanced
+practice thrombosis residency program.((Carlin, S. (2021, February 10). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220501184628/https://covid19-sciencetable.ca/wp-content/uploads/2021/02/Declaration-of-Interest_Drugs-and-Biologics-Clinical-Practice-Guidelines-Working-Group_Stephanie-Carlin-1.pdf))
+She also received joint payment from [[pharmaceutical_companies:Bristol-Myers Squibb]] and [[pharmaceutical_companies:Pfizer]] for an "educational presentation to health professionals on atrial fibrillation.((Carlin, S., & Eikelboom, J. (2022). //Advances in anticoagulation: patients with bioprosthetic heart valves.// Cardiovascular Research, 118(3), e26–e28. https://doi.org/10.1093/cvr/cvab360))